Friday, May 6, 2022 at 10:30 a.m. (EDT)
A Phase 2a Study of TPN-101 in Patients with C9ORF72 ALS/FTD
After registering, you will receive a confirmation email containing information about joining the webinar.
The purpose of this webinar is to provide an overview of a new clinical study for people living with ALS and a mutation in the C9orf72 gene. We will describe the scientific rationale for the study, the investigational drug (TPN-101), eligibility criteria, and what study participation involves. This webinar will also share contact information for interested individuals to learn more about study participation.
Past ALS Association/NEALS Webinars